PD0325901

Licensed by Pfizer 製品コードS1036

PD0325901化学構造

分子量(MW):482.19

PD0325901は一種の選択性的で、非ATP競争性的なMEK阻害剤で、無細胞試験でIC50値が0.33 nMですが、ERK1とERK2のリン酸化を抑制する作用はCI-1040より500倍左右が高くなります。臨床2期。

サイズ 価格 在庫  
USD 176 あり
USD 88 あり
USD 340 あり
USD 970 あり

文献中の引用(89)

カスタマーフィードバック(16)

  • Phosphorylation of PPARg in epididymal white adipose tissue in ob/ob mice after treatment with MEK inhibitors. Gene expression in ob/ob epididymal white adipose tissue after treatment with vehicle or either of two MEK inhibitors, PD0325901 or GSK1120212 (n = 7, 7 and 8, respectively). Areas under the curve and gene expression were analysed by analysis of variance.

    Nature 2015 517(7534), 391-5. PD0325901 purchased from Selleck.

    Rapamycin reduces VCAM expression in vivo. Expression of VCAM-1 mRNA (normalized to CD31) in aortas harvested from mice pretreated with vehicle, rapamycin, or rapamycin + MEK inhibitor (MEK-I; PD0325901) and then injected with TNF (n = 5 per group). Mice were treated as in D. Harvested aortas were analyzed for VCAM-1 expression via immunofluorescence.

    J Exp Med 2014 211(3), 395-404. PD0325901 purchased from Selleck.

  • Plasma MEK inhibitor levels of PD325901 are plotted against % MEK inhibition in brain. One hundred percent pERK levels (0% MEK inhibition) were determined in vehicle-treated rats.Inhibition of pERK activity in brain, lung, and Colo205 tumor in nude xenograft mice treated with 10 mg/kg PD325901.

     

     

    Cancer Res 2009 PD0325901 purchased from Selleck.

    Pharmacological inhibition of MEK (PD0325901) suppresses DR5 expression in cancer cells; this effect is reversible upon stopping of the treatment. The indicated cancer cell lines were exposed to the given concentrations of the inhibitors as indicated for 16 h. TPC-1 cells were treated with 10 uM of the indicated inhibitors for different times as labeled.

    Oncogene 2015 10.1038/onc.2015.97. PD0325901 purchased from Selleck.

  • (B)Effect of MAPK pathway inhibition on FGF9 mediated induction of Fgf23 expression. (D) Western blot analysis of FRS2 and ERK1/2 phosphorylation in UMR 106 cells. Cells were treated for 3h (Western blot) or 24h (qPCR analysis) with FGF9 (50ng/ml), EGF (50ng/ml), PD173074 (250nM), PD0325901 (100nM) and RAF265 (500nM) as indicated. Heparin (10g/ml) was added to all treatments with FGF9. Activation of Fgf23 is shown relative to transcript levels in vehicle treated cells (relative expression of 1). Expression values were normalized to Gapdh mRNA copies and are given as average with SEM (n3). Data were compared by 1 way ANOVA; asterisk indicates p<0.05 with respect to vehicle treated cells.

    J Bone Miner Res 2011 26, 2486-2497. PD0325901 purchased from Selleck.

    Assessment of in vivo toxicity to MEK inhibitor PD0325901. (A) Weight change in grams is shown for each PD0325901 (PD) treatment group in the MDA-MB-453 xenograft model. Weight change is the difference between pre- and post-treatment weight in each group. PD0325901 treatments were carried out at 5, 10, 15 and 20 mg/kg/day for 30 days, and daily gavage of carrier solution was used as control. *P < 0.01 for PD-5/PD-10 vs. control groups and PD-5/PD-10 vs. PD-15/PD-20 groups using Mann-Whitney U test. Error bars: ±2 SEM. (B) Number of days lost due to toxicity is shown for each PD0325901 treatment group in mouse xenograft model explained in Figure 5A. *P < 0.01 for PD-5/PD-10 vs. PD-15/PD-20 groups.

     

     

    Breast Cancer Res 2011 13, R36. PD0325901 purchased from Selleck.

  • The therapeutic effect of AR and MEK inhibitors on in vivo angiogenesis. (A) Angiogenesis index for each in vivo treatment group. Angiogenesis was measured as the number of CD-31-positive blood vessels in a cross-section of each xenograft tumor. CTL: control group; FLU: flutamide; and PD: PD0325901. *P < 0.03 for PD0325901 monotherapy vs. control and **P < 0.03 for combination therapy vs. monotherapy groups using Mann-Whitney U test. Error bars: ±2 SEM. (B) Immunohistochemistry (IHC) was used to measure angiogenesis in a control xenograft tumor. Staining was performed using a CD31 rabbit polyclonal antibody. Original magnification, × 40. (C) IHC was used to measure angiogenesis in a PD0325901 monotherapy tumor. Original magnification, × 40. (D) IHC was used to measure angiogenesis in a xenograft tumor treated with combination therapy. Original magnification, × 40.

    Breast Cancer Res 2011 13, R36. PD0325901 purchased from Selleck.

    Effects of the MEK inhibitor (MEKi) PD0325901 (PD) and rhBMP-2 (BMP) treatment on histology in an NF1 open fracture model. Treatment with 10 mg/kg of PD0325901 on days 22 through 10 (PD alone) slightly improved bone volume and callus size. Delivery of 10 mg of rhBMP-2 in the collagen sponge (BMP alone) resulted in a large increase in bone volume and callus size. Combination treatment with local rhBMP-2 and systemic PD0325901 (PD 1 BMP) resulted in further increases in new bone volume and total callus volume.Picro Sirius Red and Alcian Blue staining to assess fibrous tissue.

    J Bone Joint Surg Am 2015 96(14), e117. PD0325901 purchased from Selleck.

  • Bone 2014 59, 151-61. PD0325901 purchased from Selleck.

     

    Effect of small molecule inhibitors on reprogramming efficiency of myoblast cell derived from 5 different donors. (A) Reprogramming efficiency is shown as number of colonies from 10^5 starting cells on Y-axes. Ctrl, control condition and addition of small molecule inhibitors are marked. (B) AP staining of reprogrammed myoblast cell lines,from 5 different donors, in wells of 12-well plates at day 18. Ctrl, control condition and additions of small molecule inhibitors are marked.

    Stem Cells Dev 2013 PD0325901 purchased from Selleck.

  •  

    Characterization of rES cells. A: image of normal rES cell colonies on feeder layers. B: rES colonies were positive for AP staining. CeE: rES colonies readily expressed pluripotent markers, Sox2 (C), Oct4 (D), and SSEA-1 (E). Blue, DAPI. Scale bars: 100 um.

    J Genet Genomics 2012 39, 643e651. PD0325901 purchased from Selleck.

    The effects of PD0325901 on the Akt/mTOR and MAPK pathways in the two DDLS cell lines as evaluated by western blotting

    Tumour Biol, 2016, 37(4):4767-76.. PD0325901 purchased from Selleck.

  • PD0325901 inhibited the sorafenib-induced RAS/ERK pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (PD0325901, 10 μM). Expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (PD0325901, 10 μM). Expressions of p-AKT and cleaved PARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. Proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. Proportions of apoptotic cells were evaluated by annexin V labeling. (*P<0.05, HUH- 7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. PD0325901 purchased from Selleck.

    Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. PD0325901 purchased from Selleck.

  • Breast cancer cells were pretreated with 100ng/ml EGF for 15 min and then treated with the indicated concentrations of  PD0325901 for 24 hours.

     

     

    2010 Dr Zhang of Tianjin Medical University. PD0325901 purchased from Selleck.

    Effects of PD0325901 on HT29 Xenograft tumors. PD0325901(1mg/kg carrier DMSO).Collection at 24h.

     

     

    2010 Dr. Citrin, Deborah of NIH. PD0325901 purchased from Selleck.

製品安全説明書

MEK阻害剤の選択性比較

生物活性

製品説明 PD0325901は一種の選択性的で、非ATP競争性的なMEK阻害剤で、無細胞試験でIC50値が0.33 nMですが、ERK1とERK2のリン酸化を抑制する作用はCI-1040より500倍左右が高くなります。臨床2期。
靶点
MEK [1]
(Cell-free assay)
0.33 nM
In vitro試験

PD0325901 shows higher permeability than CI-1040, another MEK inhibitor. PD0325901 should be able to achieve higher systemic exposures than CI-1040. [1] PD0325901 is exquisitely specific and highly potent against purified MEK, revealing a Kiapp of 1 nM against activated MEK1 and MEK2. [2] PD0325901 is roughly 500-fold more potent than CI-1040 with respect to its cellular effects on phosphorylation of ERK1 and ERK2, displaying subnanomolar activity. [2] PD0325901 prevents the growth of melanoma cell lines. PD0325901 inhibits the growth of TPC-1 cells and K2 cells with GI50 of 11 nM and 6.3 nM, respectively. [3] PD0325901 significantly prevents the the growth of PTC cells harboring a BRAF mutation at very low concentration (10 nM) and only moderately increases the growth of the PTC cells carrying the RET/PTC1 rearrangement at the same concentration. PD0325901 effectively inhibits the phosphorylation of ERK1/2 in multiple PTC cell lines. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human CHP-212 cell MmrGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWTJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlUzPyCwTT6= M{jXT3NCVkeHUh?=
human M14 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIjYNHdKdmirYnn0bY9vKG:oIHj1cYFvKE1zNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFUhdk1w M{\MbHNCVkeHUh?=
human SK-MEL-28 cell Ml;QS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3ns[2lvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVI5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS53MjDuUU4> MXnTRW5ITVJ?
human NOMO-1 cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEjYfmZKdmirYnn0bY9vKG:oIHj1cYFvKE6RTV:tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvODdibl2u NWH6fndmW0GQR1XS
human A375 cell MmHGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXzJcohq[mm2aX;uJI9nKGi3bXHuJGE{PzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lk[5JI5ONg>? M12xN3NCVkeHUh?=
human DU-4475 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHnYe4RKdmirYnn0bY9vKG:oIHj1cYFvKESXLUS0O|Uh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjV5IH7NMi=> NH7ObJJUSU6JRWK=
human C32 cell NGPqSGxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGPCO4hKdmirYnn0bY9vKG:oIHj1cYFvKEN|MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOlchdk1w NUTuNndCW0GQR1XS
human BPH-1 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX;UfXZmUW6qaXLpeIlwdiCxZjDoeY1idiCEUFitNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQTVibl2u M1XNT3NCVkeHUh?=
human CP50-MEL-B cell M4q4WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVSyeI1EUW6qaXLpeIlwdiCxZjDoeY1idiCFUEWwMW1GVC2EIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND61PEBvVS5? NULtSpdQW0GQR1XS
human H9 cell NHHPXWFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NInK[ZhKdmirYnn0bY9vKG:oIHj1cYFvKEh7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT63O{BvVS5? MoTPV2FPT0WU
human HTC-C3 cell NEPv[GFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M33EOmlvcGmkaYTpc44hd2ZiaIXtZY4hUFSFLVOzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU45QSCwTT6= M{nvNnNCVkeHUh?=
human BHT-101 cell NGPuXFdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1;2RmlvcGmkaYTpc44hd2ZiaIXtZY4hSkiWLUGwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPyCwTT6= NXTQXnVoW0GQR1XS
human COLO-741 cell M1Hsbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnzVTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUe0NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOSCwTT6= NIrCcGJUSU6JRWK=
human OVCAR-5 cell NFz4eodIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVjJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlgzKG6PLh?= NFnhSVRUSU6JRWK=
human A549 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{LremlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuPFkhdk1w NXX5N|FVW0GQR1XS
human SH-4 cell growth NGO2fXhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXvDWZEyUW6qaXLpeIlwdiCxZjDoeY1idiCVSD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE4zPiCwTT6= NEnWSnVUSU6JRWK=
human SK-N-AS cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHPNO|RKdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tRXMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05NjR2IH7NMi=> NGnxUppUSU6JRWK=
human HT-144 cell M2Pmfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1XFSGlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUS0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE46PyCwTT6= NX63Rpp1W0GQR1XS
human MEL-HO cell NF3lU5ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV;Jcohq[mm2aX;uJI9nKGi3bXHuJG1GVC2KTzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmuOFkhdk1w MkXVV2FPT0WU
human COLO-679 cell MlnpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIjIW5hKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tOlc6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTBwMEGgcm0> NGOxVY9USU6JRWK=
human HuP-T4 cell NXvR[nlbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHHFTotKdmirYnn0bY9vKG:oIHj1cYFvKEi3UD3UOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExNjl6IH7NMi=> NHiwVIlUSU6JRWK=
human H-EMC-SS cell NUHBWYh7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXHJcohq[mm2aX;uJI9nKGi3bXHuJGguTU2FLWPTJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvODJibl2u Mke1V2FPT0WU
human LB2518-MEL cell MlmyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUPJcohq[mm2aX;uJI9nKGi3bXHuJGxDOjVzOD3NSWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOS5zMzDuUU4> NILLRlNUSU6JRWK=
human HL-60 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmLWTY5pcWKrdHnvckBw\iCqdX3hckBJVC14MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGxMlE2KG6PLh?= MVXTRW5ITVJ?
human NCI-H1666 cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFnk[|dKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY3PiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFzLkG3JI5ONg>? NFO0NoxUSU6JRWK=
human A101D cell MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV7pZ5RzUW6qaXLpeIlwdiCxZjDoeY1idiCDMUCxSEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyNjR3IH7NMi=> NU\0[WJ3W0GQR1XS
human RVH-421 cell MmrrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX3Jcohq[mm2aX;uJI9nKGi3bXHuJHJXUC12MkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNk43PCCwTT6= M1q4b3NCVkeHUh?=
human Hs-578-T cell Mm\XS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYnpU4xxUW6qaXLpeIlwdiCxZjDoeY1idiCKcz21O|guXCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF{Lke5JI5ONg>? NHqw[nlUSU6JRWK=
human A375 cells Mn7VVJJwdGmoZYLheIlwdiCjc4PhfS=> NF60XFQ4OiCq MWDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF|N{WgZ4VtdHNiZYjwdoV{e2mwZzDCVmFHKFZ4MEDFJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscEB1cXSncj3ncI8h[XO|YYmsJGlEPTB;MUOgcm0v M4TKNlI{PDd2M{i4
human DOK cell MnXYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4\jV2lvcGmkaYTpc44hd2ZiaIXtZY4hTE:NIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUOuOEBvVS5? NGrMU2RUSU6JRWK=
human Mewo cell MmTuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1jWZ2lvcGmkaYTpc44hd2ZiaIXtZY4hVWW5bzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG0MlQ2KG6PLh?= M2CzfnNCVkeHUh?=
human ONS-76 cell NXXiXnp2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4DCPWlvcGmkaYTpc44hd2ZiaIXtZY4hV06VLUe2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVQvPTFibl2u NYPveoNWW0GQR1XS
human UACC-257 cell NWDzPZlZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M16wcWlvcGmkaYTpc44hd2ZiaIXtZY4hXUGFQz2yOVch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPC54MjDuUU4> Mnu1V2FPT0WU
human SW626 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGDVUJdKdmirYnn0bY9vKG:oIHj1cYFvKFOZNkK2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVQvQTFibl2u NVfac2VkW0GQR1XS
human SW620 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4LCdmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d4MkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOE46PSCwTT6= NFnvNYlUSU6JRWK=
human TYK-nu cell M3HQVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV;ONpNIUW6qaXLpeIlwdiCxZjDoeY1idiCWWVutcpUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yPS5zMzDuUU4> M3q2N3NCVkeHUh?=
human ACN cell NXXjPJZ2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3LmUmlvcGmkaYTpc44hd2ZiaIXtZY4hSUOQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUWuO|Yhdk1w MWDTRW5ITVJ?
human MIAPaCa2 cells MorJVJJwdGmoZYLheIlwdiCjc4PhfS=> MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2LQWDhR4EzKGOnbHzzMEBKSzVyPUG3JI5ONg>? MY[yN|Q4PDN6OB?=
human T-24 cell NVHaZo5GT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUHhN3BxUW6qaXLpeIlwdiCxZjDoeY1idiCWLUK0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVkvPzFibl2u NFXaXJlUSU6JRWK=
human AGS cell NV3P[4V3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmXTTY5pcWKrdHnvckBw\iCqdX3hckBCT1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{MD60NUBvVS5? NETuPHJUSU6JRWK=
human SW872 cell MoPDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1vBNGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d6N{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yO{46QSCwTT6= NH61ZpBUSU6JRWK=
human C2BBe1 cell MnfUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3jiTmlvcGmkaYTpc44hd2ZiaIXtZY4hSzKEQnWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlgvPTRibl2u Mo\5V2FPT0WU
human MZ7-mel cell MmP6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MorxTY5pcWKrdHnvckBw\iCqdX3hckBOYjdvbXXsJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlkvPDNibl2u NXntUY1mW0GQR1XS
human HCC2998 cell M3vaOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYrJcohq[mm2aX;uJI9nKGi3bXHuJGhESzJ7OUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zN{43PiCwTT6= MmPCV2FPT0WU
human HO-1-N-1 cell NXfLbXBiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH\1d5pKdmirYnn0bY9vKG:oIHj1cYFvKEiRLUGtUk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzRwNEOgcm0v NGDjbnNUSU6JRWK=
human SW756 cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2jiVmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5NU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zOE41PSCwTT6= MnK4V2FPT0WU
human NCI-H1437 cell MlPtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3;KcGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOFM4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzRwNEmgcm0v NWTkXHVlW0GQR1XS
human NCI-H747 cell Mle1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoTlTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEe0O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM1Njl6IH7NMi=> NGniUGVUSU6JRWK=
human SK-MEL-2 cell Mn3jS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkTPTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM2NjJibl2u NWO2ZphDW0GQR1XS
human MZ2-MEL cell M1vNfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXXifHVvUW6qaXLpeIlwdiCxZjDoeY1idiCPWkKtUWVNKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzVwNkWgcm0v NWTGRZRFW0GQR1XS
human PSN1 cell M1fLZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYjUS5dMUW6qaXLpeIlwdiCxZjDoeY1idiCSU16xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|gvPDVibl2= Mmm0V2FPT0WU
human CAL-39 cell M4K3Zmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWX3[mZRUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytN|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{QS5yNDDuUU4> MVnTRW5ITVJ?
human LOXIMVI cell Mk\DS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYfJcohq[mm2aX;uJI9nKGi3bXHuJGxQYEmPVlmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zPU4{QSCwTT6= Mn;xV2FPT0WU
human COLO-792 cell M3XyOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmXqTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUe5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ{NjF3IH7NMi=> NX;E[Yp5W0GQR1XS
human CAL-27 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV;qR3Z[UW6qaXLpeIlwdiCxZjDoeY1idiCFQVytNlch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01PC57MTDuUS=> MnfLV2FPT0WU
human AsPC-1 cell M3jGbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkLKTY5pcWKrdHnvckBw\iCqdX3hckBCe1CFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20OU4zQCCwTT6= NIDU[5RUSU6JRWK=
human NCI-H2291 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHLuWVlKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlI6OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTR4LkS2JI5ONg>? NYq1e|M2W0GQR1XS
human RCM-1 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mk\XTY5pcWKrdHnvckBw\iCqdX3hckBTS01vMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS2Mlg2KG6PLh?= MoDhV2FPT0WU
human NCI-H292 cell NU\XbpB2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn;FTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEK5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQ4NjN7IH7NMi=> M2S4bnNCVkeHUh?=
human WM-115 cell NGjRSmFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4PWcmlvcGmkaYTpc44hd2ZiaIXtZY4hX01vMUG1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFgvPSCwTT6= NYLTOoZYW0GQR1XS
human RT-112 cell M2HQfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYjJcohq[mm2aX;uJI9nKGi3bXHuJHJVNTFzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS4Mlg1KG6PLh?= NVK0cnl2W0GQR1XS
human HT-29 cell NWDHXGZDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NF;GV21KdmirYnn0bY9vKG:oIHj1cYFvKEiWLUK5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OVAvPDlibl2u MmDOV2FPT0WU
human RKO cell growth MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M33nfGlvcGmkaYTpc44hd2ZiaIXtZY4hWkuRIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUKuNFIhdk1w NVPLd5I2W0GQR1XS
human KY821 cell NIDFZ4dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4f6V2lvcGmkaYTpc44hd2ZiaIXtZY4hU1l6MkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21N{4{KG6PLh?= NHu4PIxUSU6JRWK=
human LB1047-RCC cell MlL1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NG\ZdJFKdmirYnn0bY9vKG:oIHj1cYFvKEyEMUC0O{1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13OT62OUBvVS5? MUTTRW5ITVJ?
human SW1116 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1[x[2lvcGmkaYTpc44hd2ZiaIXtZY4hW1dzMUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OlAvPDlibl2u NUHVeZpiW0GQR1XS
human P12-ICHIKAWA cell M{jh[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mlq3TY5pcWKrdHnvckBw\iCqdX3hckBROTJvSVPITWtCX0FiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14Mj6yO{BvVS5? MVLTRW5ITVJ?
human HCC70 cell NFnhVHhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYfJcohq[mm2aX;uJI9nKGi3bXHuJGhESzdyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NkOuNFEhdk1w NWnNUFB1W0GQR1XS
human MIA-PaCa-2 cell M2L5Smdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1\pRWlvcGmkaYTpc44hd2ZiaIXtZY4hVUmDLWDhR4EuOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZ|LkWzJI5ONg>? NH;pVFNUSU6JRWK=
human LoVo cell M1j6bGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXHJcohq[mm2aX;uJI9nKGi3bXHuJGxwXm9iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14NT6yPUBvVS5? M{fOPHNCVkeHUh?=
human LB2241-RCC cell NV7TOG1vT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIjwSY1KdmirYnn0bY9vKG:oIHj1cYFvKEyEMkK0NU1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14NT61NkBvVS5? M{Tl[nNCVkeHUh?=
human GAK cell M1z5Zmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGrZPYFKdmirYnn0bY9vKG:oIHj1cYFvKEeDSzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[2Mlg4KG6PLh?= NWfV[GpnW0GQR1XS
human RD cell MmK1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWnJcohq[mm2aX;uJI9nKGi3bXHuJHJFKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjdwMTDuUU4> MV;TRW5ITVJ?
human KNS-62 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXHJcohq[mm2aX;uJI9nKGi3bXHuJGtPWy14MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[5Mlk6KG6PLh?= MUnTRW5ITVJ?
human HD-MY-Z cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHPTVZVKdmirYnn0bY9vKG:oIHj1cYFvKEiGLV3ZMXoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04OS5zMjDuUU4> M2HWUXNCVkeHUh?=
human COR-L105 cell MlvGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3vTeWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVyxNFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04OS55MTDuUU4> M{SxcXNCVkeHUh?=
human IA-LM cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF\kR3ZKdmirYnn0bY9vKG:oIHj1cYFvKEmDLVzNJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O|MvOjhibl2u M4\DR3NCVkeHUh?=
human EM-2 cell NEnicZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4PySGlvcGmkaYTpc44hd2ZiaIXtZY4hTU1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUe0Mlchdk1w MYrTRW5ITVJ?
human NB69 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIrkOYpKdmirYnn0bY9vKG:oIHj1cYFvKE6ENkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfS=> MVHTRW5ITVJ?
human HuP-T3 cell M{PYZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkWwTY5pcWKrdHnvckBw\iCqdX3hckBJfVBvVEOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24N{46OyCwTT6= MnvRV2FPT0WU
human BB30-HNC cell NYrXbXNtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFXidVNKdmirYnn0bY9vKG:oIHj1cYFvKEKEM{CtTG5EKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QDVwNUGgcm0v NYW3XIwxW0GQR1XS
human HT-1080 cell MlHpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M13NTWlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVg2Njh6IH7NMi=> MWnTRW5ITVJ?
human RMG-I cell NHTMRY1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlHMTY5pcWKrdHnvckBw\iCqdX3hckBTVUdvSTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUi3MlM1KG6PLh?= NU[0WolOW0GQR1XS
human HCC1419 cell M2DMOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF7HSY9KdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{G0NVkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06OS5|ODDuUU4> NYjVeJR3W0GQR1XS
human SW780 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIX4d|VKdmirYnn0bY9vKG:oIHj1cYFvKFOZN{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PVIvOzJibl2u NE\5SoNUSU6JRWK=
human SNU-387 cell MlW4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mm\UTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvM{i3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PVMvOzZibl2= NHzDZXRUSU6JRWK=
human LAMA-84 cell NXPzWINkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3fxTGlvcGmkaYTpc44hd2ZiaIXtZY4hVEGPQT24OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVk1NjZ6IH7NMi=> NYjIZXpyW0GQR1XS
human MV-4-11 cell NYCxepZTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIPpUo1KdmirYnn0bY9vKG:oIHj1cYFvKE2YLUStNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF06PC55MzDuUU4> NHXOVpdUSU6JRWK=
human EGI-1 cell M2XW[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MonCTY5pcWKrdHnvckBw\iCqdX3hckBGT0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUm1MlgyKG6PLh?= NVfPUopbW0GQR1XS
human NCI-SNU-1 cell NIXHRXhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3:xe2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLWPOWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QTZwN{Ogcm0v NI\NN|FUSU6JRWK=
human MEG-01 cell MorzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFrzeFdKdmirYnn0bY9vKG:oIHj1cYFvKE2HRz2wNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVk4Njd5IH7NMi=> MXTTRW5ITVJ?
human OMC-1 cell NVKzVI82T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGraNphKdmirYnn0bY9vKG:oIHj1cYFvKE:PQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVAxNjJ|IH7NMi=> NUfpNI93W0GQR1XS
human NB10 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYPWTWlOUW6qaXLpeIlwdiCxZjDoeY1idiCQQkGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVAxNjR{IH7NMi=> NILwW4tUSU6JRWK=
human CAL-62 cell M1[0cGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4LYb2lvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLU[yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVAxNjd6IH7NMi=> M{XU[HNCVkeHUh?=
human NCI-H2087 cell M4PSfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIXD[2JKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA5PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFyMT6xOEBvVS5? NIfXXXlUSU6JRWK=
human MDA-MB-175-VII cell NYDhNWdDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUmycJVxUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOTd3LW\JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6 Mkj0V2FPT0WU
human LS-513 cell NV7KUYt{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{nqXGlvcGmkaYTpc44hd2ZiaIXtZY4hVFNvNUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVE1Njh|IH7NMi=> MlyxV2FPT0WU
human HN cell growth Mmf1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXjJcohq[mm2aX;uJI9nKGi3bXHuJGhPKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTJ{LkW5JI5ONg>? M17aRXNCVkeHUh?=
human ABC-1 cell M3Xkbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFTUenVKdmirYnn0bY9vKG:oIHj1cYFvKEGEQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVI{NjB{IH7NMi=> M{nRcnNCVkeHUh?=
human SJSA-1 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml\3TY5pcWKrdHnvckBw\iCqdX3hckBUUlODLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNlMvOTlibl2u M2mwd3NCVkeHUh?=
human PANC1 cells NGrJd3JHfW6ldHnvckBie3OjeR?= M{SwUFExKM7:TR?= NE\vXm8yKGh? NXyxZ5FpUW6qaXLpeIlwdiCxZjDNSWsyKGmwIHj1cYFvKFCDTlOxJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCyRYLrNU8zKGyndnXsJIF1KDFyIIXNJIFnfGW{IEGgbJIh[nliV3XzeIVzdiCkbH;0eIlv\yCjbnHsfZNqew>? NYmzcVJEOjV5Nk[2N|M>
human MCF7 cells MV;GeY5kfGmxbjDhd5NigQ>? MYS3OUBucW6| M{\xPWlvcGmkaYTpc44hd2ZiTVXrNU8zKGmwIHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hTVKNIIDoc5NxcG:{eXzheIlwdiCjZoTldkA4PSCvaX7zJIJ6KFenc4Tldo4h[myxdITpcoch[W6jbInzbZM> MkXNNlM{QTh2NUO=

... Click to View More Cell Line Experimental Data

In vivo試験 The improved potency of PD0325901 relative to CI-1040 is evident. A single oral dose of PD0325901 (25 mg/kg) inhibits phosphorylation of ERK by more than 50% at 24 hours post-dosing. In contrast, CI-1040 at a much higher dose (150 mg/kg) only inhibit pERK levels for roughly 8 hours, returning to control levels by 24 hours after treatment. [2] Therefore, the dose required to produce a 70% incidence of complete tumor responses (C26 model) is 25 mg/kg/day versus 900 mg/kg/day for PD0325901 and CI-1040, respectively. Anticancer activity of PD 0325901 has been demonstrated for a broad spectrum of human tumor xenografts. [2] After 1 week of oral administration of PD0325901 (20–25 mg/kg/day) in mice, no tumor growth is detected in mice inoculated with PTC cells bearing a BRAF mutation. [3] For PTC with the RET/PTC1 rearrangement, the average tumor volume of the orthotopic tumor is decreased by 58% as compared with controls. In conclusion, PTC cells carrying a BRAF mutation are more sensitive to PD0325901 than are PTC cells carrying the RET/PTC1 rearrangement. [3]

プロトコル(参考用のみ)

キナーゼアッセイ:

[1]

+ 展開

In vitro cascade assay:

Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of a glutathione S-transferase fusion protein containing p44MAP kinase (GST-MAPK) and a glutathione S-transferase protein containing p45MEK (GST-MEK). The assay solution contained 20 mM HEPES, pH 7.4, 10 mM MgCl2, 1 mM MnCl2, 1 mM EGTA, 50 mM [gamma-32P]ATP, 10 mg GST-MEK, 0.5 mg GST-MAPK and 40 mg MBP in a final volume of 100 mL. Reactions are stopped after 20 minutes by addition of trichloroacetic acid and filtered through a GF/C filter mat. 32P retained on the filter mat is determined using a 1205 Betaplate. PD0325901 is assessed at various dose ranges in order to determine dose response curves.
細胞アッセイ:

[3]

+ 展開
  • 細胞株: PTC cells
  • 濃度: 0.1 nM- 1 μM
  • 反応時間: 48 hours
  • 実験の流れ:

    PTC cells (1 × 104) are seeded in 24-well plates with 1 mL of medium for 4 days in a 37 °C incubator. MEK inhibitor PD0325901 at varying concentrations is added to the cells in triplicate on day 0. MTT dissolved in 0.8% NaCl solution at 5 mg/mL is added to each well (0.2 mL) on day 2 to test GI50 or every day for cell growth curves. The cells are incubated at 37 °C for 3 hours with MTT. The liquid is then aspirated from the wells and discarded. Stained cells are dissolved in 0.5 mL of DMSO and their absorption at 570 nm is measured using a Synergy HT multidetection microplate reader. For GI50, cell growth is calculated as 100 × (T − T0)/(C − T0), where T is the optical density of the wells treated with inhibitors after a 48-hour period, T0 is the optical density at time zero, and C is the control optical density with DMSO only.


    (参考用のみ)
動物実験:

[3]

+ 展開
  • 動物モデル: Ncr-nu/nu mice bearing PTC cells
  • 製剤: 80 mM citric buffer (pH 7)
  • 投薬量: 20-25 mg/kg
  • 投与方法: Oral gavage
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 96 mg/mL (199.09 mM)
Ethanol 40 mg/mL (82.95 mM)
Water <1 mg/mL
体内 30% PEG 400+5% Tween 80+ddH2O 10mg/mL

* <1 mg/mlは製品が微弱に溶解する或いは溶解しないことを示します。
* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 482.19
化学式

C16H14F3IN2O4

CAS No. 391210-10-9
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02510001 Recruiting Solid Tumour|Colorectal Cancer University of Oxford|Queens University, Belfast|Oxford University Hospitals NHS Trust|Velindre NHS Trust|University Hospital, Antwerp|Hospital Vall dHebron|Hopital St Antoine, Paris|European Georges Pompidou Hospital|Pfizer|University of Turin, Italy|Belfast Health and Social Care Trust|Beaumont Hospital|European Commission|Array BioPharma|Q2 solutions|Covance|QPS Holdings November 2014 Phase 1
NCT02096471 Active, not recruiting Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN University of Alabama at Birmingham June 2014 Phase 2
NCT02022982 Recruiting KRAS Mutant Non-Small Cell Lung Cancer|Solid Tumors Dana-Farber Cancer Institute January 2014 Phase 1|Phase 2
NCT02039336 Recruiting Colorectal Cancer The Netherlands Cancer Institute|Pfizer January 2014 Phase 1|Phase 2
NCT02297802 No longer available Prior Treatment With PD-0325901 With Ongoing Clinical Response Sharp HealthCare June 2013 Phase 1
NCT01347866 Terminated Advanced Cancer Pfizer October 2011 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Whether the inhibitor PD0325901 interacts with other targets other than MEK?

  • 回答:

    PD0325901 has very high selectivity to MEK. In addition, it can also inhibits VEGF activity according to the reference: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713590/

MEK信号経路図

MEK Inhibitors with Unique Features

相関MEK製品

Tags: PD0325901を買う | PD0325901 ic50 | PD0325901供給者 | PD0325901を購入する | PD0325901費用 | PD0325901生産者 | オーダーPD0325901 | PD0325901化学構造 | PD0325901分子量 | PD0325901代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID